|
Market Cap (5-Jun) $61,568,592 (1,444th) |
Close (30-Jun) $0.076 |
Volume (30-Jun) 120,981 |
Shortsold (26-May) 11,577 (0.00%) (629th) |
|
52w High $0.425 |
52w Low $0.056 |
P/E - |
EPS -0.02 |
ATX released this announcement to the ASX on 30 September 2021, 9:07. The announcement is marked as price sensitive, and is 2 page(s) in length and 158.96kb in size.
You can view all announcements from ATX and see how they appear on a price chart on the announcements page.
At the date of this announcement, ATX was 0.012% short sold according to ASIC data. It was ranked the 606th most shorted stock on the ASX. It remains ranked 629th as of the latest reported data (26 May 2026).
| Other Recent Announcements from ATX | |
|---|---|
| AMP945 International Nonproprietary Name Narmafotinib | 21 June 2023, 8:34 |
| Amplia AGM to be held Thursday 24 August 2023 | 19 June 2023, 17:34 |
| Key to Corporate Governance Disclosures | 31 May 2023, 8:14 |
| New Garvan Publication Supports Amplia Phase 2 Design | 30 September 2021, 9:07 |
| Proactive Investors Lifesciences Webinar Presentation | 28 September 2021, 8:25 |
| Amplia to Present at Proactive Investor Lifesciences Webinar | 27 September 2021, 8:40 |
| Phase 2 Trial in First-Line Pancreatic Cancer Patients | 15 September 2021, 9:10 |
You must be logged in to post a reply.
Amplia Therapeutics 